modern cardiac diagnostics

Caring Technology
Passion for working smarter

Acarix works to revolutionize cardiac diagnostics.

About us

Acarix A/S is based on pioneering research performed at the Aalborg University, Denmark, initiated in 2004. The research group received the award, ‘MedicoPrisen’, from Medicoindustrien (Danish Medtech trade association) in 2007. A research and development collaboration was established in 2007 between Aalborg University and Coloplast A/S, receiving public support from the Danish National Advanced Technology Foundation in 2008.

Acarix was established in 2009 as a spin-out from Coloplast A/S, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016.



Acarix can be reached by email at for general questions or information.

Requests for information on the company, financial or clinical/technical issues can also be forwarded directly to CFO Christian Lindholm or COO Claus Bo Vöge Christensen respectively.

We try to answer promptly and within 24 hours.

Our Management Team

  • Christian Lindholm Interim CEO / CFO since 2016.

    Christian Lindholm has during the last 17 years held positions as CFO within both private and listed companies. Prior to joining Acarix Christian was CFO at Doro AB and TFS International AB. Christian Lindholm has studied economy at University of Växjö and Kristianstad.

    Acarix shareholdings:
    Shares: 2.000
    Warrants: 25.500

    +46 705 118 333

  • Claus Bo Vöge Christensen Chief Operating Officer since 2009

    Claus Bo Vöge Christensen has experience from own research, including managing experience from research departments and research projects from start-up companies doing product- and business innovation through market- and user studies. At Acarix Claus Bo Vöge Christensen has partly been executing clinical studies and processes leading to CE-registration, and fully engaged in product development and production. Claus Bo Vöge Christensen has previous experience from Novozymes A/S, MIC-DTU and latest from Coloplast A/S, being responsible for ”Medical Monitoring & Diagnostics” from where Acarix A/S was initiated. Claus Bo Vöge Christensen has an MBA from The Technical University of Denmark and a PhD in Molecular biology from University of Copenhagen, Denmark.

    Shares: 154.982
    Warrants: 112.500

    +45 2972 4411

  • Dr. Anja Schaefer Chief Marketing Officer since 2016. (Engaged in Acarix through consultancy agreement.)

    Anja Schaefer has since 2014 been CEO of strategy consultancy company TaRes GmbH, Germany. She has more than 25 years experience in the health care industry including international leadership roles for pharmaceutical and medical device companies in various commercial and medical affairs functions. Anja succesfully launched innovative products and managed all live cicle stages for broad product portfolios with a focus on Cardiology since 1995. She holds a PhD in molecular genetics from The Max Planck Institute in Berlin, Germany.

    Acarix shareholdings:
    Shares: 2.500
    Warrants: 0


    +49 171 8343085

Where to contact us

Acarix AS

Acarix AB

  • World Trade Center, Skeppsgatan 19, SE-211 11 Malmö Sweden